PHOENIX, Ariz. Aug. 30, 2013 Rex Griswold, Vice President of Sales for Nestl Waters North America, was a driving force at the company for more than two decades until Multiple System Atrophy (MSA) suddenly struck him.
Initially, he noticed his right side was not in sync with his left. He had problems walking, his handwriting deteriorated, and his speech became slurred. Doctors thought at first he might have had a stroke. After many, many other tests, it was determined he had MSA.
"The biggest problem is there's no hope for the patient who's got it," Griswold said. "No matter how many doctors you go to, they all say the same thing: there is no cure for MSA. There are not enough people with the disease, so there's no research being done. There's hardly anything to hang on to."
Under the banner, "Quest to Cure MSA in honor of Rex Griswold," the Translational Genomics Research Institute (TGen) today was tapped to conduct the world's most in-depth genomic investigation into the causes of MSA.
The project is funded by a $100,000 grant from the CARRE (Charitable Alliance of Restaurant and Retail Executives) Foundation, part of CSP Business Media. MSA was selected as the beneficiary of a 2013 CARRE Foundation fundraising event in honor of Nestl's Rex Griswold.
"After meeting with TGen senior leadership and faculty, we knew they were the right scientific institute to conduct this groundbreaking research," said David Jobe, President, CSP Business Media Leadership Conferences. "We believe this is only the beginning and that, with the help and support of the greater community, we are on our way toward discovering the causes of this debilitating disease."
Kay Segal, Senior Vice President of CSP Business Media, agreed: "We are confidentbased on TGen's leadership, faculty and state-of-the-art genomic capabilitiesthat we have found an exceptional partner in this battle to find a cure."
Kim E. Jeffery, Chair
|Contact: Steve Yozwiak|
The Translational Genomics Research Institute